Results for tag: "Lebrikizumab"

Lebrikizumab is a humanized monoclonal antibody used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). It works by blocking the action of interleukin-13 (IL-13), a cytokine that plays a role in the inflammation and airway remodeling associated with these diseases. Lebrikizumab is administered as an intravenous infusion and is approved for use in adults and adolescents aged 12 years and older. The lebrikizumab market is a rapidly growing segment of the respiratory drugs market. It is expected to benefit from the increasing prevalence of asthma and COPD, as well as the growing demand for targeted therapies. Lebrikizumab is a promising treatment option for patients with severe asthma, as it has been shown to reduce exacerbations and improve lung function. Some companies in the lebrikizumab market include Genentech, AstraZeneca, and GlaxoSmithKline. These companies are actively researching and developing lebrikizumab for the treatment of respiratory diseases. Show Less Read more